Optimal Prophylactic Method of Venous Thromboembolism (VTE)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2014 by The Catholic University of Korea.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Kyo Young Song, The Catholic University of Korea
ClinicalTrials.gov Identifier:
First received: October 5, 2011
Last updated: January 28, 2014
Last verified: January 2014
This study is to define the optimal method of prophylaxis for patients with gastrectomy in Korea and the investigators hypothesized only mechanical method would be enough for preventing VTE on perioperative period.

Condition Intervention Phase
Venous Thromboembolism
Drug: low molecular weight heparin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
Official Title: Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients

Resource links provided by NLM:

Further study details as provided by The Catholic University of Korea:

Primary Outcome Measures:
  • incidence of VTE [ Time Frame: up to 30 days after operation ] [ Designated as safety issue: No ]
    The incidence of VTE between mechanical method only group and mechnical plus LMWH group.

Secondary Outcome Measures:
  • Adverse event [ Time Frame: up to 30 days after operation ] [ Designated as safety issue: Yes ]
    The adverse event such as bleeding will also be compared.

Estimated Enrollment: 682
Study Start Date: October 2011
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: intermittent pneumatic compression
another arm include intermittent pneumatic compression plus low molecular weight heparin
Drug: low molecular weight heparin
40mg 12 hours before surgery and 12 hours later surgery

Detailed Description:

Venous thromboembolism (VTE) is common and often fatal complication in patients with cancer.

Gastric cancer is the most frequent cancer in Korea.

The incidence of VTE would be increased in patients with gastric cancer, especially associated surgery.

However, the incidence and optimal prophylactic method associated with cancer surgery are not well studied in Asian patients.

Most Korean surgeon concerns regarding the increased postoperative bleeding associated with low molecular weight heparin(LMWH)prophylaxis.

The incidence and adverse event will be examined to define the optimal prophylactic method of VTE in surgical patients with gastric cancer.


Ages Eligible for Study:   20 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients diagnosed as gastric cancer
  • Elective and curative under general anesthesia
  • ECOG score 0-2
  • ASA score 3 or less than 3
  • Informed consents

Exclusion Criteria:

  • 2nd primary cancer
  • VTE history within one year
  • Anticoagulation history
  • Allergic to heparin
  • Pregnancy or expected pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01448746

Contact: Kyo Young Song, M.D. +82222586106 skys9615@gmail.com

Korea, Republic of
Seoul St. Mary's Hospital Recruiting
Seoul, Korea, Republic of, 137701
Contact: Kyo Young Song, M.D.    +82222586106    skys9615@gmail.com   
Sponsors and Collaborators
The Catholic University of Korea
Principal Investigator: Kyo Young Song, M.D. The Catholic University of Korea
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Kyo Young Song, Associate Professor, The Catholic University of Korea
ClinicalTrials.gov Identifier: NCT01448746     History of Changes
Other Study ID Numbers: CUMC-GC2011 
Study First Received: October 5, 2011
Last Updated: January 28, 2014
Health Authority: Korea: Institutional Review Board

Keywords provided by The Catholic University of Korea:
gastric cancer

Additional relevant MeSH terms:
Venous Thromboembolism
Cardiovascular Diseases
Embolism and Thrombosis
Vascular Diseases
Heparin, Low-Molecular-Weight
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on April 27, 2016